Please find attched herewith the outcome of Board Meeting dated 11th August, 2026.

Date: 11th August, 2026 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Limited 1st Floor, Phiroze Jeejeebhoy Towers, "Exchange Plaza" Dalal Street, Fort, Sandra Kurla Complex, Sandra (E), Mumbai - 400 001 Mumbai - 400 051. Scrip Code: 506235 NSE Symbol: ALEMBICL TD Dear Sir, Sub: Outcome of Board Meeting With reference to the captioned subject, the exchanges are hereby informed that the Board of Directors of Alembic Limited at its meeting held today has inter alia approved the Unaudited Financial Results of the Company for the quarter ended 3Qth June, 2026: We enclose herewith the following:· a) Consolidated Unaudited Financial Results for the quarter ended 30th June, 2026. b) Standalone Unaudited Financial Results for the quarter ended 3Q1h June, 2026. c) Limited Review Report by Statutory Auditors on the Consolidated and Standalone Unaudited Financial Results. The time of commencement of the Board Meeting was 3:30 p.m. · and the time of conclusion was 4:00 p.m. We request you to kindly take the same on record. Thanking you, Yours faithfully, ompany Secretary Encl.: A/a ALEMBIC LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA- 390 003. •TEL: (0265) 6637000 website: www.alemblclimited.com •E-mail: alembic.investors@alembic.co.in • CIN: L26100GJ1907PLC000033 ALEMBIC LIMITED Cl N :L26100GJ l907PLC000033 Regd.Office: Alembic Road, Vadodara 390 003 Ph:0265 6637000 www.alemblclimlted.com Email:alemblc.lnvestors@alembic.co.ln Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2026 Rs. in Lakhs Quarter Ended Year Ended Sr. 30.06.2926 31.03.2026 30.06.2025 31.03.2026 No Particulars (Unaudited) (Audited) (Unaudited) (Audited) 1 Revenue from Operations 4,874 6,004 4,975 23,999 2 Other Income 596 214 359 7,297 3 Total Income 5,471 6,218 5,334 31,296 4 Expenses Cost of Materials Consumed 493 404 345 1,388 Cost of Construction 862 1,463 1,010 6,002 Changes in Inventories of Finished Goods and WIP (51) (65) 174 255 Employee Benefit Expenses 1,046 1,174 783 3,744 Finance Costs 60 57 59 228 Depreciation and amortisation expense 348 334 279 1,239 Other Expenses 979 1,006 705 3,564 Total Expenses 3,737 4,374 3,356 16,420 5 Profit Before Tax (3-4} 1,734 1,844 1,978 14,876 6 Tax Expenses Current Tax 193 566 202 2,263 Deferred Tax (29) 287 (3) (10) Short/ (Excess} Provision of earlier years - 30 - 30 7 Net Profit after tax for the Period 1,570 961 1,780 12,593 8 Share of Associate's Profit/(Loss) 4,919 5,752 4,384 19,145 9 Net Profit/(Loss} after tax and Share of Associate's Profit/(Loss} 6,489 6,713 6,164 31,738 10 Other Comprehensive Income A (i} Items that will not be reclassified to Profit or (Loss) 7,048 (11,724) 482 (10,562} (ii} Income tax relating to items that will not be reclassified to Profit or (Loss) (752) 1,241 (69) 925 B (i) Items that will be reclassified to Profit or (Loss) 90 384 31 882 (ii) Income tax relating to items that will be reclassified to Profit or Loss (14} - - - 11 Total Comprehensive lncome/(Loss) for the Period 12,860 (3,387) 6,609 22,983 12 Paid up Equity Share Capital (Face Value of Rs 2/- per share) 5,135.64 5,135.64 5,135.64 5,135.64 13 Other Equity (excluding Revaluation Reserve} 2,24,927 14 Earnings per equity share (FV Rs. 2/- per share) 2.53 2.61 2.40 12.36 Basic & Diluted (In Rs.) Alembic Limited Segment wise Consolidated Revenue and Results Rs In Lakhs Quarter Ended Year Ended Sr. 30.06.2026 31.03.2026 30.06.2025 31.03.2026 No Particulars (Unaudited) (Audited) (Unaudited) (Audited) 1 Segment Revenue Revenue from Operations a. Active Pharmaceutical Ingredients Business 1,171 983 1,295 4,659 b. Real Estate Business 3,703 5,021 3,680 19,340 Total Income from Operations (Net) 4,874 6,004 4,975 23,999 2 Segment Results (Profit(+)/ Loss(·) before Taxes and Interest from each segment) a. Active Pharmaceutical Ingredients Business 166 {117) 273 565 b. Real Estate Business 1,398 2,097 1,594 8,117 Total 1,564 1,980 1,867 8,682 Unallocable Income and Expenditure (i) Interest Expense {60) {57) (59) {228) (ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset 220 {121) 171 6,167 (iii) Other Income/ (Expense) 11 42 0 255 Total Profit Before Tax 1,734 1,844 1,978 14,876 3 Segment Assets a. Active Pharmaceutical Ingredients Business 18,228 18,081 19,170 18,081 b. Real Estate Business 52,873 51,578 46,822 51,578 c. Unallocated 2,00,856 1,89,291 1,86,165 1,89,291 Total 2,71,957 2,58,951 2,52,158 2,58,951 4 Segment Llabilltles a. Active Pharmaceutical Ingredients Business 3,577 3,480 3,647 3,480 b. Real Estate Business 7,765 8,148 10,857 8,148 c. Unallocated 3,247 2,814 3,356 2,814 Total 14,588 14,442 17,861 14,442 Notes: 1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company. 2 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter/ year. 3 The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2026 and year to date unaudited figures upto third quarter ended 31st December, 2025. For Alembic Limited Place : Vadodara UditAmin Date : 11th August, 2026 Managing Director ALEMBIC LIMITED CIN:L26100GJ1907PLC000033 Regd.Office: Alembic Road, Vadodara 390 003 Ph:0265 6637000 www.alembiclimited.com Email:alembic.investors@alembic.co.ln Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2026 Rs. In Lakhs Quarter Ended Year Ended Sr. 30.6.2026 31.3.2026 30.06.2025 31.03.2026 No. Particulars (Unaudited) (Audited) (Unaudited) (Audited) l Revenue from Operations 4,627 5,773 4,789 23,193 2 Other Income 555 241 346 7,277 3 Total Income 5,182 6,014 5,134 30,470 4 Expenses Cost of Materials Consumed 493 404 345 1,388 Cost of Construction 862 1,463 1,010 6,002 Changes in Inventories of Finished Goods and WIP (51) (65) 174 255 Employee Benefit Expenses 1,046 1,174 783 3,744 Finance Costs 37 37 42 157 Depreciation and amortisation expense 338 325 270 1,201 Other Expenses 873 841 619 3,035 Total Expenses 3,598 4,180 3,243 15,781 5 Profit Before Tax (3-4) 1,584 1,834 1,892 14,689 6 Tax Expenses CurrentTax 159 550 180 2,200 Deferred Tax (44) 301 (0) 5 Short/ (Excess) Provision of earlier years - 30 30 7 Net Profit after tax for the Period 1,468 953 1,712 12,454 8 Other Comprehensive income (i) Items that will not be reclassified to Profit or (Loss) 7,062 (11,668) 495 (10,363) (ii) Income tax relating to items that will not be reclassified to Profit or (Loss) {756) 1,240 {71) 898 9 Total Comprehensive lncome/(Loss) for the Period 7,774 {9,476) 2,136 2,989 10 Paid up Equity Share Capital (Face Value of Rs 2/- per share) 5,135.64 5,135.64 5,135.64 5,135.64 11 Other Equity (excluding Revaluation Reserve) 62,564 12 Earnings per equity share (FV Rs. 2/- per share) 0.57 0.37 0.67 4.85 Basic & Diluted (In Rs.) Alembic Umlted Rs In Lakhs Segment wise Standalone Revenue and Results Sr. Quarter Ended Year Ended No. Particulars 30.06.2026 31.3.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 Segment Revenue Revenue from Operations a. Active Pharmaceutical Ingredients Business 1,171 983 1,295 4,659 b. Real Estate Business 3,455 4,790 3,493 18,535 Total Income from Operations (Net) 4,627 5,773 4,789 23,193 2 Segment Results (Profit(+)/ Loss(-) before Taxes and Interest from each segment) a. Active Pharmaceutical Ingredients Business 166 (117) 273 565 b. Real Estate Business 1,224 2,067 1,490 7,859 Total 1,391 1,950 1,763 8,424 Unallocable Income and Expenditure (i) Interest Expense (37) (37) (42) (157) (ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset 220 (121) 171 6,167 (iii) Other Income/ (Expense) 11 42 0 255 Total Profit Before Tax 1,584 1,834 1,892 14,689 3 Segment Assets a. Active [Showing first 8,000 characters — download PDF for full document]